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understandably, anxious to avoid relapse once they have found a
helpful therapy.
It is satisfying to read at last of a psychiatrist acknowledging the
mood-elevating effect of oestrogens, and intriguing to observe the
contrasting press coverage of their article which presents the
increased "well-being" as a complication of dependence. We have
published four randomised controlled trials showing that
oestrogens improve postnatal’ and premenstrual depression2,3 and
climacteric depression,4 the triad of potentially oestrogen-
responsive affective disorders, without one letter of protest or
support from psychiatrists. By contrast, the Bewleys’ paper was
reported on the front page of The Times, with the proclamation that
"HRT can be as addictive as heroin"-a claim, incidentally, that the
Bewleys do not make.
I have no doubt that many patients formerly distressed by
insomnia, fatigue, and depression (and antidepressants or the
occasional episode of electroconvulsive therapy) are dependent on
the good health they achieve when on effective HRT. Is this really a
cause for concern? There are certainly women who return for
oestrogen implants more frequently than advised, and those who
self-medicate with extra oestrogen tablets or oestradiol patches.
These women have experienced a good response to the normal dose,
and the problem is one of inappropriate expectations: "more" is
regarded as "better". These women may need higher levels of
oestradiol to obtain symptomatic relief, since many were originally
treated for premenstrual syndrome (PMS) or climacteric
depression. There may also be a greater incidence of psychiatric
morbidity in this group. 5
With implants symptoms return after 4-8 months, even though
oestradiol levels are normal.6 An oestradiol implant removes
symptoms whereas a placebo implant does not.7 These symptoms
would thus seem to be a result of changes in oestradiol levels rather
than absolute low levels. This is the basis of our hypothesis that the
symptoms of PMS and postnatal depression are due to similar
changes in sex hormones, and that the symptoms respond to an
increase in plasma oestradiol levels and abolition of these
fluctuations. As patients return with oestrogen-responsive
symptoms for a repeat oestradiol implant, there is an increase of
plasma oestradiol sometimes into the supraphysiological range
equivalent to that found in the first month of pregnancy. It is a
matter of debate whether this is dependence or merely the blood
level necessary to control symptoms in patients who have been
severely depressed.
The important question is whether these higher levels of
oestradiol have a harmful end-organ response, especially on the
breast. The only study comparing the incidence of breast cancer in
women with oestrogen implants with that in women with lower
oestradiol levels of oral oestrogens did not reveal any difference in
risk.9 On the other hand, a major beneficial effect of higher
oestradiol levels is the greater incremental increase in bone density
obtained with implants, which is directly proportional to the
oestradiol level achieved.’o
I must protest that oestrogens are not "reputed to stop ageing".
This may be the view of the tabloid press or even the mistaken belief
of vulnerable women, but it is not a view held by any researcher or
by even the most crusading zealot for HRT.
The Menopause Clinic,
Dulwich Hospital
London SE22 8PT, UK JOHN STUDD
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Norharman, a normal body constituent
SIR,-Norharman is an aromatic unsubstituted &bgr;-carboline.
This substance might be a natural ligand of benzodiazepine binding
sites. Norharman also has comutagenic activity.2 A distinct class of
high-affinity binding sites (Kp, 1 -55 nmol/1) for norharman in rat
brain has lately been demonstrated.3 Norharman has been found
endogenously in rats by two groups of investigators. 4,5 However, so
far norharman has not been detected in human blood, probably
because the procedure used was not sensitive enough.’ To increase
the sensitivity of our norharman assay we modified both the sample
clean-up and high performance liquid chromatography (HPLC)
procedures. We now present evidence that norharman is a normal
body constituent.
Plasma obtained from blood of 23 healthy donors was subjected
to solid phase extraction on ’C-18 Seppack’ (Millipore) columns.
The main modifications of the procedure6 were: the extraction
buffer contained no NaClO4 and the pH was 7-7 rather than 40,
7-15 ml plasma samples were applied directly onto the C-18
cartridges instead of a mixture of 4 volumes of plasma (15 ml) and 1
volume of 5 x concentrated extraction buffer. Norharman
concentrations were measured by HPLC with hamian as internal
standard. The main difference with the earlier method6 was that the
ion-pair former sodium octyl sulphate was omitted in the eluent,
because a fully endcapped ’Zorbax C8’ column (Dupont) was used.
1 5 fmol norharman could be detected with a signal to noise ratio of
3. With this method plasma concentrations of down to 01 nmol/l
norharman could be measured. The mean (SD) plasma norharman
concentration of the 23 healthy controls was 0-23 (0-22) nmol/l
(range 01-07).
The positive identification of norharman was confirmed by liquid
chromatography-mass spectrometry (LC-MS) in three different
laboratories. In one system, the norharman containing fraction
obtained after HPLC was derived with pentafluorobenzoyl chloride
and injected onto a RP-6 fully capped ’Phase Sep’ reversed-phase
column. Norharman was detected on line in the negative chemical
ionisation mode with a ’Finnigan’, model 4021, mass spectrometer.
The other two laboratories used a thermospray LC-MS system (an
’HP 1090’ liquid chromatograph coupled to an ’HP 5988A’ mass
spectrometer and a ’Varian 5000’ liquid chromatograph coupled to a
’Finnigan MAT TSP’ mass spectrometer). Although our findings
do not elucidate endogenous formation of norharman in man, we can
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